NCT06780826View on ClinicalTrials.gov

A Study on the Efficacy of Atezolizumab Combined with Chemotherapy

RecruitingOBSERVATIONAL
Enrollment

1,430

Participants

Timeline

Start Date

August 28, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

September 30, 2025

Conditions
Lung Cancer, Small Cell
Interventions
DRUG

Atezolizumab

Atezolizumab, 1200 mg intravenous infusion, 21 days per cycle

DRUG

Etoposide

Etoposide,intravenous infusion, 100mg/m,21 days per cycle

DRUG

Carboplatin

carboplatin,intravenous infusion, AUC=5, 21 days per cycle.

Trial Locations (1)

200433

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER